<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650168</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2013_08</org_study_id>
    <nct_id>NCT01650168</nct_id>
  </id_info>
  <brief_title>Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)</brief_title>
  <acronym>PRO-E2</acronym>
  <official_title>Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Theramex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the risks of short- and long-term use of NOMAC-E2 (containing a fixed
      dose of nomegestrol acetate and estradiol) compared with levonorgestrel-containing combined
      oral contraceptives (COC-LNG) in a study population representative of the actual users of the
      individual preparations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOMAC-E2 is a novel monophasic oral contraceptive containing a fixed dose of nomegestrol
      acetate (2.5mg) and 17ß-estradiol (1.5mg) which is taken for 24 days followed by 4 days of
      placebo. The most relevant adverse clinical outcome that has been linked to the use of COCs
      is venous thromboembolism (VTE). Data from randomized clinical trials did not show any
      serious health concerns for NOMAC-E2. However, the statistical power to detect rare adverse
      events is limited in these studies.

      PRO-E2 is a large, prospective, controlled, long-term active surveillance study to
      investigate the safety of NOMAC-E2 with regard to the outcomes of interest. This study
      follows the European Active Surveillance (EURAS) design methodology with some modifications
      due to country- and product-specific characteristics. The outcomes of interest will be
      validated via the attending physicians. A multi-faceted follow-up procedure will ensure a low
      loss to follow-up rate. This study will involve women from Europe and Australia who will be
      followed for up to 2 years. Data analysis will include multivariable techniques such as Cox
      regression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolisms (VTE)</measure>
    <time_frame>Within 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial thromboembolisms (ATE)</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive disorders</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholelithiasis</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bowel disease</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short- and long-term fertility</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug utilization pattern</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General hepatobiliary disorders</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acne</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">101000</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>NOMAC-E2</arm_group_label>
    <description>New users of NOMAC-E2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LNG-COCs</arm_group_label>
    <description>New users of levonorgestrel-containing COCs</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women using oral contraceptives
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First ever user of a COC (&quot;starter&quot;)

          -  User who restarts hormonal contraceptive use with a COC (same COC as before or a new
             COC) after an intake break of at least two months (&quot;restarters&quot;)

          -  Women willing to participate in the active surveillance

        Exclusion Criteria:

        - Women who do not understand the major aspects of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Dinger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suzanne Reed, MSc, PhD</last_name>
    <phone>+49 30 945 101 63</phone>
    <email>reed@zeg-berlin.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klaas Heinemann, MD, PHD</last_name>
    <phone>+49 30 945 101 20</phone>
    <email>k.heinemann@zeg-berlin.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>May 17, 2017</last_update_submitted>
  <last_update_submitted_qc>May 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NOMAC-E2</keyword>
  <keyword>Nomegestrol acetate</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Levonorgestrel</keyword>
  <keyword>Safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

